Cart (0)
Your shopping cart is empty!
Biosib.com
Lavomax (Tiloron) 0,125 N6
Lavomax (Tiloron) 0,125 N6
Product Code: 208193

Lavomax (Tiloron) 0,125 N6

Compare this Product
$19.00
In Stock

Expiration date: 01/2019 

The composition and form of issue:

Tablets, film-coated 1 tablet contains:

tiloron 0.125 g

auxiliary substances: to obtain the tablet weight of 0.39 g of magnesium hydroxycarbonate hydrate (magnesium carbonate basic aqueous) povidone (PVP low molecular weight medical, kollidon) calcium stearate silicon dioxide colloidal (Aerosil) beeswax mineral oil sucrose talc tropeolin 0 titanium dioxide polyethylene glycol of high molecular weight 6000 

in a contour acheikova packing 6 or 10 PCs in a pack a cardboard 1 or 2 packs.

Description pharmaceutical form:

Tablets, film-coated from yellow to orange, round shape. In the cross-section are seen 2 layers. - Tablet — orange.

Pharmacological action:

Stimulates the body &alpha-, &beta-, &gamma-interferons. The main producers of interferon in response to the introduction of Lavomax are the cells of the intestinal epithelium, hepatocytes, T-lymphocytes and neutrophils. After intake of maximum production of interferon is defined in the sequence intestine-liver-blood through 4-24 h. Lavomax ® has immunomodulating and antiviral effect.

Stimulates stem cells of bone marrow, depending on the dose increases antibody production, reduces the degree of immunosuppression, restores the ratio of T-helper/T - suppressor. Effective against various viral infections, including against influenza, other acute respiratory viral infections, hepatitis viruses, herpes viruses. The mechanism of antiviral action is associated with inhibition of translation of virus-specific proteins in infected cells, resulting in suppressed reproduction of viruses.

Pharmacokinetics:

After intake of rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. The plasma protein binding is about 80%.

No biotransformation and accumulation in the body.

Excreted almost unchanged in the faeces (70%) and urine (9%). T1/2 is 48 h.

Indications:

  • viral hepatitis A, B, C
  • herpes infection CMV infection
  • infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, avioanele, etc.), urogenital and respiratory chlamydia, negonokokkovi urethritis, tuberculosis (complex therapy)
  • influenza and other ARVI in adults (treatment and prevention).

Contraindications:

  • hypersensitivity to the drug
  • pregnancy and lactation
  • children up to age 18 years.

Side effects:

Allergic reactions, diarrhoeal phenomenon, intermittent fever.

Drug interactions:

Compatible with antibiotics and traditional means of treatment of viral and bacterial diseases. Clinically meaningful interaction Lavomax with these drugs have not been identified.

Method of application and dose:

Inside, after eating.

For non-specific prevention of viral hepatitis A — 0.125 g per week for 6 weeks.

For the treatment of viral hepatitis And 0.125 g 2 times on the first day, and then on the 0,125 grams a day. Heading dose — 1.25 g (10 table.).

For the treatment of acute hepatitis b: first and second days to 0,125 grams and then on the 0,125 grams a day dose is 2 g (16 table). When protracted course of hepatitis b 0.125 g 2 times a day for the first day, and then on the 0,125 grams a day. The course dose of 2.5 g (20 table.)

In chronic hepatitis b in the initial phase of treatment (2.5 g — 20 table.): in the first 2 days — 0.25 g, 0.125 g a day. The continuation phase from 1.25 g (10 table.) to 2.5 g (20 table.) — 0.125 g per week. Heading dose of Lavomax to 3.75–5 g (30 to 40 tab. 0.125 g), the duration of treatment is 3.5–6 months depending on the results of biochemical, immunological and morphological studies, reflecting the degree of activity of the process.

In acute hepatitis C: in the first and second days to 0,125 grams and then on the 0,125 grams a day. The course dose of 2.5 g (20 table.)

In chronic hepatitis C, in the initial phase of treatment (2.5 g — 20 table.): in the first two days — 0.25 g, 0.125 g a day. The continuation phase (2.5 g — 20 table). — 0.125 g per week. Heading dose of Lavomax — 5 g (40 tab. 0.125 g), the duration of therapy — 6 months depending on the results of biochemical, immunological, morphological markers of activity of the process.

In the treatment of influenza and other ARVI in the first two days of illness — 0,125 grams and then on the 0,125 grams a day. Heading dose is 0.75 g (6 table. 0.125 g).

For the prevention of influenza and other acute respiratory viral infections: 0,125 1 g once a week for 6 weeks. On the course — 6 table. 0.125 g.

For the treatment of herpes and CMV infection in the first two days to 0,125 grams and then on the 0,125 grams a day. The course dose of 2.5 g (20 table. 0.125 g).

At the urogenital and respiratory chlamydia: the first two days to 0,125 grams and then on the 0,125 grams a day. Heading dose — 1.25 g (10 table. 0.125 g).

In complex therapy neyrovirushnykh infections: a dose set individually, of treatment is 4 weeks.

In the complex treatment of pulmonary tuberculosis: first two days at 0.25 g then on the 0,125 grams a day. The course dose of 2.5 g (20 table. 0.125 g).

Overdose:

Cases overdose unknown.